一本一本久久a久久综合精品蜜桃,西西人体大胆午夜视频,国产女人18毛片水真多1

Vividion Gains Rights to Covalent WRN Inhibitor VVD-214 from Roche Bayer Vividion Therapeutics Roche Bayer’s Vividion Therapeutics secures exclusive global rights to VVD-214, the only clinical-stage covalent WRN inhibitor, from Roche. The drug shows early promise for treating MSI-high cancers in phase 1 trials.
Bicara and Merus Compete in HNSCC Drug Development Race ASCO Bicara Merus Bicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
Proposed NIH Cancer Research Cuts Spark Industry Concern ASCO Trump NIH NCI The Trump administration’s proposed budget cuts to NIH and NCI risk hindering cancer research progress, prompting strong opposition from ASCO and ACS CAN over potential impacts on patient outcomes and innovation.
Kura and Kyowa's Ziftomenib Shows 23% Remission in AML Trial ASCO Market Trend FDA Kura Oncology and Kyowa Kirin announced a 23% remission rate in their phase 2 trial of oral leukemia drug ziftomenib for relapsed/refractory NPM1-mutant AML, with FDA approval under review and phase 3 trials planned.
Sanofi Strengthens STAT6 Pipeline with Nurix Sanofi Nurix Sanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
Regeneron Secures $2B Deal for Hansoh’s Obesity Drug Rivaling Zepbound Regeneron Hansoh Pharma Regeneron signs a $2B deal with Hansoh Pharma for HS-20094, a GLP-1/GIP receptor agonist aimed at rivaling Eli Lilly’s Zepbound in the obesity market. The deal boosts Regeneron's obesity pipeline with late-stage drug access and new combo therapy potential.
Bristol Myers Joins BioNTech in $11B Bispecific Pact BMS BioNTech Bristol Myers Squibb partners with BioNTech in an $11B deal to co-develop the PD-L1xVEGF-A bispecific BNT327, strengthening its immuno-oncology portfolio amid rising competition from Merck and Pfizer.
ASCO 2025: 14 Chinese ADC Therapies Showcase Strong Efficacy Across Multiple Tumors ASCO Market Trend ADC At ASCO 2025, 14 Chinese ADC therapies demonstrated impressive efficacy and safety across various cancers, including breast, lung, gastric, and urothelial, signaling strong global potential for domestically developed treatments.
Intellia’s Gene Therapy Nex-z Faces Safety Concern but Analysts Remain Positive Intellia Therapeutics Intellia Therapeutics' gene therapy nex-z saw a stock dip after a grade 4 liver enzyme elevation in a phase 3 trial, but analysts remain confident in its safety and clinical potential for treating ATTR and hereditary angioedema.
FDA Rejects Elamipretide Despite Support, Stealth Biotherapeutics Plans Resubmission FDA Stealth Biotherapeutics Stealth Biotherapeutics faces FDA rejection for elamipretide, a treatment for Barth syndrome, despite a favorable advisory vote. The company plans a resubmission amid layoffs and calls for swift regulatory action.